Swiss National Bank Sells 215,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Swiss National Bank cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,127,900 shares of the company’s stock after selling 215,000 shares during the quarter. Swiss National Bank owned approximately 0.28% of Teva Pharmaceutical Industries worth $68,939,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Atria Investments Inc lifted its stake in Teva Pharmaceutical Industries by 135.4% in the third quarter. Atria Investments Inc now owns 30,856 shares of the company’s stock worth $556,000 after purchasing an additional 17,746 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $60,000. Victory Capital Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 1,928,715 shares of the company’s stock valued at $34,755,000 after acquiring an additional 21,764 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in Teva Pharmaceutical Industries by 68.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company’s stock valued at $584,000 after acquiring an additional 13,215 shares during the period. Finally, CIBC Asset Management Inc grew its position in Teva Pharmaceutical Industries by 5.7% during the 3rd quarter. CIBC Asset Management Inc now owns 105,463 shares of the company’s stock worth $1,900,000 after acquiring an additional 5,713 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TEVA. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, March 7th. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 0.5 %

Shares of NYSE:TEVA opened at $16.38 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The firm has a market capitalization of $18.57 billion, a P/E ratio of -11.29, a P/E/G ratio of 1.44 and a beta of 0.82. The stock has a 50 day moving average price of $18.28 and a 200-day moving average price of $18.29.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.